The Phase II trial of phenylbutyrate for pediatric patients with progressive or recurrent CNS malignancies addresses a significant unmet need in the treatment of childhood brain tumors. Given the limited therapeutic options available for this patient population, successful outcomes could position phenylbutyrate as a novel treatment modality, enhancing its commercial viability. The pediatric oncology market is characterized by high demand for innovative therapies, especially for rare and aggressive tumor types. Competitive analysis should focus on existing treatments for similar indications, including chemotherapeutic agents and emerging therapies. Diligence should assess the potential for partnership or licensing opportunities with larger pharmaceutical companies, particularly those with established oncology portfolios.